76. ESMO 2023 - Colorectal Cancer (Part 2)

Metastatic colorectal cancer has an average overall survival of three years. With limited treatment options as standard of care or effective targetable mutations, ESMO23 shined, providing answers to unanswered questions and a potentially brighter future for this cancer. Concerningly, we are seeing higher rates of colorectal cancer in lower and middle-income countries and those under the age of 50. We explore sotorasib in KRASG12C mutated cancers with panitumumab, the use of aspirin to reduce the risk of cancer recurrence and whether triplet therapy is better than double in potentially resectable colorectal cancer.Studies discussed in today's episode (subscription may be required)Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III studyhttps://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638992First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Grouphttps://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639062Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639177For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at [email protected] courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.